Proactive Investors - Run By Investors For Investors

Re-organisation sees Instem 'better positioned for profitable growth'

Phil Reason, chief executive Instem Plc (LON:INS), caught up with Proactive to discuss their first half 2017 numbers.

Total revenues were up 13% to £10.3m (H1 2016: £9.1m) while recurring revenues saw a nice increase of 23% to £6.5m (H1 2016: £5.3m).

Meet ImmuPharma PLC, Synairgen plc, Tissue Regenix Group PLC, Tissue Regenix Group PLC and WideCells Group at our event, London, 02 November 2017. Register here »
Why Invest In Instem Plc? Read More Here

Register here to be notified of future Instem Plc articles
View full INS profile View Profile

Instem Plc Timeline

Big Picture
September 19 2016

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use